静脉注射对乙酰氨基酚用于剖宫产术后疼痛控制的随机对照试验
该双盲、安慰剂对照随机试验纳入104例择期剖宫产产妇,比较静脉注射对乙酰氨基酚1000 mg与生理盐水安慰剂每8小时一次共48小时共6剂的效果。结果显示对乙酰氨基酚组口服阿片类药物消耗量显著低于安慰剂组(47 mg vs 65 mg羟考酮,P = .034),疼痛评分及阿片类药物副作用无显著差异。
要点
- 择期剖宫产术后静脉注射对乙酰氨基酚1000 mg每8小时一次共48小时共6剂,可显著减少口服阿片类药物消耗量。
- 对乙酰氨基酚组口服羟考酮总量47 mg,安慰剂组65 mg,差异有统计学意义(P = .034)。
- 两组疼痛评分及阿片类药物副作用(恶心/呕吐、呼吸抑制、便秘)无显著差异。
核心结论
- 剖宫产术后静脉注射对乙酰氨基酚可显著减少用于疼痛控制的口服阿片类药物消耗量。
研究设计与样本
- 经机构审查委员会批准的双盲、安慰剂对照随机试验,在clinicaltrials.gov注册(编号02046382)。
- 招募足月、拟在区域麻醉下接受剖宫产的产妇,所有围手术期及产后护理通过研究医嘱套餐标准化。
- 研究药物为对乙酰氨基酚1000 mg静脉注射或100 mL生理盐水(安慰剂),每8小时一次共48小时,总计6剂。
- 药房将静脉注射对乙酰氨基酚与生理盐水装入相同给药袋并标注研究药物以确保盲法,首剂在皮肤切开后60分钟内给予。
- 功效计算确定每组需45例患者,以80%功效和P = .05显著性水平检测剖宫产术后麻醉药需求量减少30%。
主要发现
- 共133例患者签署知情同意,29例被排除,104例完成研究:57例接受静脉注射对乙酰氨基酚,47例接受安慰剂。
- 基线人口学特征(年龄、体重指数、孕次、产次、种族、合并症、既往剖宫产次数)无差异。
- 两组估计失血量或住院时间无差异。
- 对乙酰氨基酚组口服阿片类药物消耗总量显著低于安慰剂组(47 mg vs 65 mg羟考酮;P = .034)。
- 两组布洛芬使用总量无差异,研究给药前后疼痛评分无差异,阿片类药物副作用(恶心/呕吐、呼吸抑制、便秘)无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cesarean delivery is a common surgery in the United States, with 1.3 million performed during 2009.1 Obstetricians must balance the growing concern with opioid abuse, dependence, and side effects with optimal postoperative pain control. Intravenous acetaminophen may represent an additional method to decrease the reliance on opioid medications and improve postoperative pain following cesarean delivery. OBJECTIVE: The objective of the study was to determine whether the administration of intravenous acetaminophen following routine scheduled cesarean delivery would decrease the need for narcotic medications to control postoperative pain. STUDY DESIGN: This was an institutional review board-approved, double-blind, placebo-controlled, randomized trial, registered on clinicaltrials.gov (number 02046382). Women scheduled to undergo cesarean delivery with regional anesthesia at term were recruited. All perioperative and postpartum care was standardized via study order sets. Study patients were given all medications in a standardized manner receiving either acetaminophen 1000 mg intravenously or 100 mL saline (placebo) every 8 hours for 48 hours for a total of 6 doses. The pharmacy prepared intravenous acetaminophen and saline in identical administration bags labeled study drug to ensure blinding. The initial dose of study drug was given within 60 minutes of skin incision. Quantity of breakthrough and scheduled analgesic medications and self-reported pain levels on the Faces Pain Scale (0-10) before and after study drug administration were collected. Patient demographics were extracted from the chart. Power calculation determined that 45 patients per arm were required to detect a 30% reduction in postcesarean narcotic requirement with 80% power and a significance level of P = .05. RESULTS: A total of 133 patients were consented for the study. Twenty-nine were excluded and 104 patients completed the study: 57 received intravenous acetaminophen and 47 received placebo. There were no differences in baseline demographic characteristics including patient age, body mass index, gravidity, parity, race, comorbidities, or number of prior cesarean deliveries. There were no differences between groups in estimated blood loss or length of stay. The total amount of oral narcotic medications consumed by patients receiving intravenous acetaminophen was significantly reduced when compared with the placebo group (47 mg vs 65 mg of oxycodone; P = .034). The total amount of ibuprofen used between groups was not different. There was no difference in pain scores between groups before and after study dose administration. There was no significant difference in narcotic side effects (nausea/emesis, respiratory depression, constipation) in either study arm. CONCLUSION: Intravenous acetaminophen in the postoperative period following cesarean delivery resulted in a significant decrease in oral narcotic consumption for pain control.
引用
- Altenau B, Crisp CC, Devaiah CG, et al. Randomized controlled trial of intravenous acetaminophen for postcesarean delivery pain control. Am J Obstet Gynecol. 2017. PMID: 28455085. doi:10.1016/j.ajog.2017.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。